Clinical Trials on Idiopathic Interstitial Pneumonias in Austria

Total 476 results

Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

Primary Immune Thrombocytopenia

United States, China, Germany, Spain, Singapore, Japan, Taiwan, Belgium, Italy, Czechia, Hungary, Malaysia, Korea, Republic of, Turkey, Argentina, Thailand, India, United Kingdom, France, Australia, Romania, Austria, Norway, Netherlands, Philippin...
Acorda Therapeutics

Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Idiopathic Parkinson's Disease

United States, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Serbia, Spain, United Kingdom
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
University of Pennsylvania
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS)

Microscopic Polyangiitis (MPA) | Granulomatosis With Polyangiitis (Wegener's) (GPA)

United States, Belgium, France, United Kingdom, Denmark, Canada, Japan, Australia, New Zealand, Sweden, Czechia, Italy, Greece, Mexico, Norway
Aridis Pharmaceuticals, Inc.

Completed

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

Pseudomonas Aeruginosa Pneumonia

Belgium, United States, France, Spain, Georgia, Australia, Belarus, Czechia, Greece, Hungary, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Taiwan, Ukraine
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

COVID-19 | Pneumococcal Disease | SARS-CoV-2 Infection

United States
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

COVID-19 | SARS-CoV-2 Infection | Maternal Immunization

United States, United Kingdom, Spain, Brazil, South Africa
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

COVID-19

United States, Spain, Denmark, United Kingdom
Amgen

Completed

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Canada, Belgium, Czechia, Mexico, Turkey, Australia, Spain, France, Israel, Hungary, South Africa, Poland, Russian Federation, United Kingdom, Brazil, Switzerland
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
Pfizer

Completed

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

COVID-19

Spain, United States, Australia, Canada, Bulgaria, Slovakia, Mexico, Hungary, Brazil
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Matthew Neal MD
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

Covid19

United States, Spain, Brazil, Italy
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

COVID-19 | SARS-CoV-2

United States, Chile, Peru
Medicago

Active, not recruiting

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

SARS-CoV-2 Infection

United States, Canada, United Kingdom, Argentina, Brazil, Mexico
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
Infectopharm Arzneimittel GmbH
INPADS GmbH; Dr. Oestreich + Partner GmbH

Recruiting

Fosfomycin i.v. for Treatment of Severely Infected Patients (FORTRESS)

Respiratory Tract Infections | Sepsis | Encephalitis | Bacterial Infections | Intraabdominal Infections | Bacteremia | Skin Diseases, Bacterial | Pneumonia, Bacterial | Urinary Tract Infections | Meningitis, Bacterial | Central Nervous System Bacterial Infections | Soft Tissue Infections | Endocarditis, Bacterial | Bone Diseases, Infectious and other conditions

Germany, Austria, Greece, Italy, United Kingdom
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
University of Chile
Columbia University

Recruiting

The Covid-19 HEalth caRe wOrkErS (HEROES) Study (HEROES)

Depression | Covid-19 | Anxiety | Mental Health Disorder | SARS-CoV-2 | Stress Disorder

United States, Italy, Argentina, Armenia, Australia, Bolivia, Chile, Costa Rica, Czechia, Germany, Guatemala, Lebanon, Mexico, Netherlands, Nigeria, Puerto Rico, Saudi Arabia, Spain, Tunisia, Turkey, Venezuela
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

Malignant Solid Neoplasm | COVID-19 Infection | Hematopoietic and Lymphatic System Neoplasm

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

COVID-19

United States, United Kingdom, Canada
Frank C Sciurba
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

COVID-19

United States
BioNTech SE
Pfizer

Completed

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

COVID-19 | SARS-CoV-2 Infection

United States, Brazil, South Africa, Germany, Canada, Israel
BioNTech SE
Pfizer

Completed

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

COVID-19 | SARS-CoV-2 Infection

United States, Germany, Turkey, South Africa, Argentina, Brazil
Kadmon, a Sanofi Company

Active, not recruiting

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Chronic Graft-versus-host-disease

United States
Novartis Pharmaceuticals

Completed

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Pneumonia

United States, France, United Kingdom, Spain, Belgium, Canada, Korea, Republic of, Argentina, Australia, Brazil, Chile, Germany, Malaysia, Netherlands, New Zealand, Peru, Singapore, South Africa
Pfizer

Terminated

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

COVID-19

United States, Malaysia, Thailand, Turkey, Spain, Czechia, Poland, Bulgaria, Japan, Korea, Republic of, South Africa, Hungary, Argentina, Brazil, Colombia, Mexico, Puerto Rico, Romania, Slovakia, Ukraine
Harvard Pilgrim Health Care
Brigham and Women's Hospital; Centers for Disease Control and Prevention; University... and other collaborators

Active, not recruiting

The INSPIRE-ASP PNA Trial

Pneumonia

United States
Pfizer

Completed

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

COVID-19

United States, Korea, Republic of, Russian Federation, Czechia, Turkey, Malaysia, South Africa, Bulgaria, Poland, Hungary, Argentina, Brazil, Colombia, Japan, Mexico, Puerto Rico, Spain, Thailand, Ukraine, India
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

SARS-CoV2 Infection

United States, Puerto Rico
BioNTech SE
Pfizer

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
BioNTech SE
Pfizer

Completed

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

SARS-CoV-2 Infection, COVID-19

United States, Spain, Finland, Poland, Mexico, Brazil
Pneumonia Research Network on Genetic Resistance...
Charite University, Berlin, Germany; German Federal Ministry of Education and... and other collaborators

Completed

Study of Progression of Community Acquired Pneumonia in the Hospital (PROGRESS)

Pneumonia | Sepsis | Shock, Septic

Austria, Germany
Shionogi
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

SARS-CoV-2 Infection

United States, India, Uganda, Poland, Philippines, Thailand, Pakistan, South Africa, Argentina, Brazil, Colombia, Ghana, Japan, Kenya, Malawi, Mexico, Turkey
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
Novavax
Department of Health and Human Services

Completed

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Covid19 | SARS-CoV Infection

United States, Mexico, Puerto Rico
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
Incyte Corporation

Active, not recruiting

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Chronic Graft Versus Host Disease | Myelofibrosis | Postlung Transplant (Bronchiolitis Obliterans)

United States, Spain, Italy, Germany, Belgium, Austria, Israel, Canada, Greece
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, Spain, Korea, Republic of, Australia, Austria, Canada, France, Germany, Israel, Italy, Netherlands, Russian Federation, United Kingdom
Sanofi

Recruiting

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ROCKnrol-1)

Chronic Graft Versus Host Disease

Australia, Argentina, Belgium, Spain, Sweden, Czechia, Turkey, United Kingdom, United States, Germany, Italy, Canada, Israel, Denmark, Brazil, Netherlands
Zambon SpA

Enrolling by invitation

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) (BOSTON-3)

Bronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative Bronchiolitis

France, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
University of British Columbia

Active, not recruiting

Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease (ABLE-cGVHD)

Chronic Graft vs Host Disease

Canada, United States, Austria

Clinical Trials on Idiopathic Interstitial Pneumonias in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations